Amylyx Pharmaceuticals to Participate in Investor Conferences
ByAinvest
Tuesday, Aug 26, 2025 10:09 am ET1min read
AMLX--
- Citi's 2025 Biopharma Back to School Conference: A fireside chat scheduled for Tuesday, September 2, 2025, at 1:00pm ET.
- Cantor Global Healthcare Conference 2025: A fireside chat on Wednesday, September 3, 2025, at 8:00am ET.
- Morgan Stanley 23rd Annual Global Healthcare Conference: A fireside chat on Monday, September 8, 2025, at 4:50pm ET.
- Baird 2025 Global Healthcare Conference: A fireside chat on Tuesday, September 9, 2025, at 3:10pm ET.
- H.C. Wainwright 27th Annual Global Investment Conference: A corporate presentation on Wednesday, September 10, 2025, at 10:00am ET.
Amylyx Pharmaceuticals, headquartered in Cambridge, Massachusetts, is focused on developing innovative treatments for diseases with high unmet needs. The company aims to make significant impacts in neurodegenerative and endocrine diseases through its investigational therapies [1].
Live webcasts of each conference event will be available on the company's investor section website, accessible under "Events and Presentations" [1]. These webcasts will be available for replay for 90 days following the events.
References:
[1] https://www.businesswire.com/news/home/20250821659514/en/Amylyx-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences
[2] https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-to-participate-in-upcoming-investor-f49sqlgd26cj.html
Amylyx Pharmaceuticals announced its participation in several upcoming investor conferences, including Citi's 2025 Biopharma Back to School Conference, Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, Baird 2025 Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference. Management will participate in fireside chats and corporate presentations, and live webcasts of the events will be available on the company's website.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) has announced its participation in several upcoming investor conferences, highlighting the company's commitment to transparent communication and engagement with stakeholders. The events, which will take place in-person in Boston and New York City, include:- Citi's 2025 Biopharma Back to School Conference: A fireside chat scheduled for Tuesday, September 2, 2025, at 1:00pm ET.
- Cantor Global Healthcare Conference 2025: A fireside chat on Wednesday, September 3, 2025, at 8:00am ET.
- Morgan Stanley 23rd Annual Global Healthcare Conference: A fireside chat on Monday, September 8, 2025, at 4:50pm ET.
- Baird 2025 Global Healthcare Conference: A fireside chat on Tuesday, September 9, 2025, at 3:10pm ET.
- H.C. Wainwright 27th Annual Global Investment Conference: A corporate presentation on Wednesday, September 10, 2025, at 10:00am ET.
Amylyx Pharmaceuticals, headquartered in Cambridge, Massachusetts, is focused on developing innovative treatments for diseases with high unmet needs. The company aims to make significant impacts in neurodegenerative and endocrine diseases through its investigational therapies [1].
Live webcasts of each conference event will be available on the company's investor section website, accessible under "Events and Presentations" [1]. These webcasts will be available for replay for 90 days following the events.
References:
[1] https://www.businesswire.com/news/home/20250821659514/en/Amylyx-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences
[2] https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-to-participate-in-upcoming-investor-f49sqlgd26cj.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet